This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
OPNT Aperçu des actions
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Opiant Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$20.65 |
| Plus haut sur 52 semaines | US$28.15 |
| Plus bas sur 52 semaines | US$7.34 |
| Bêta | 0.83 |
| 1Variation sur 1 mois | 3.10% |
| Variation sur 3 mois | 2.38% |
| Variation sur 1 an | -22.31% |
| 3Variation sur 3 ans | 70.80% |
| Variation sur 5 ans | 1.77% |
| Évolution depuis l'introduction en bourse | -82.79% |
Nouvelles et mises à jour récentes
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Rendement pour les actionnaires
| OPNT | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | -1.3% | -2.7% | 0.9% |
| 1Y | -22.3% | 21.0% | 32.3% |
Rendement vs Industrie: OPNT underperformed the US Pharmaceuticals industry which returned -3.7% over the past year.
Rendement vs marché: OPNT underperformed the US Market which returned 14.1% over the past year.
Volatilité des prix
| OPNT volatility | |
|---|---|
| OPNT Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: OPNT has not had significant price volatility in the past 3 months.
Volatilité au fil du temps: OPNT's weekly volatility has decreased from 19% to 1% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2005 | 38 | Roger Crystal | www.opiant.com |
Opiant Pharmaceuticals, Inc. Résumé des fondamentaux
| OPNT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$108.80m |
| Bénéfices(TTM) | -US$33.09m |
| Recettes(TTM) | US$22.34m |
4.9x
Ratio P/S-3.3x
Ratio P/ELe site OPNT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| OPNT compte de résultat (TTM) | |
|---|---|
| Recettes | US$22.34m |
| Coût des recettes | US$29.45m |
| Marge brute | -US$7.11m |
| Autres dépenses | US$25.97m |
| Les revenus | -US$33.09m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -6.28 |
| Marge brute | -31.85% |
| Marge bénéficiaire nette | -148.12% |
| Ratio dettes/capitaux propres | 67.1% |
Quelles ont été les performances à long terme de OPNT?
Voir les performances historiques et les comparaisons